208 related articles for article (PubMed ID: 38376624)
1. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer.
Sentana-Lledo D; Morgans AK
Curr Oncol Rep; 2024 Mar; 26(3):299-306. PubMed ID: 38376624
[TBL] [Abstract][Full Text] [Related]
2. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic side effects of androgen deprivation therapy in prostate cancer.
Lafontaine ML; Kokorovic A
Curr Opin Support Palliat Care; 2022 Dec; 16(4):216-222. PubMed ID: 36349380
[TBL] [Abstract][Full Text] [Related]
4. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
[TBL] [Abstract][Full Text] [Related]
6. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
[TBL] [Abstract][Full Text] [Related]
7. Nutrition Guidance for Patients on Androgen Deprivation Therapy.
Kenfield SA; Van Blarigan EL; Graff RE; Borno HT; Macaire G; Chan JM
Eur Urol Focus; 2023 May; 9(3):427-430. PubMed ID: 36935290
[TBL] [Abstract][Full Text] [Related]
8. Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives.
Kitagawa Y; Ueno S; Konaka H; Mizokami A; Hinotsu S; Akaza H; Namiki M
Curr Cancer Drug Targets; 2015; 15(4):314-26. PubMed ID: 26003144
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
10. Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.
Forster RB; Engeland A; Kvåle R; Hjellvik V; Bjørge T
Int J Cancer; 2022 Oct; 151(7):1109-1119. PubMed ID: 35489025
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
Butler SS; Mahal BA; Moslehi JJ; Nohria A; Dee EC; Makkar R; Whitbeck A; Wangoe J; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2021 Jul; 127(13):2213-2221. PubMed ID: 33905530
[TBL] [Abstract][Full Text] [Related]
12. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
[TBL] [Abstract][Full Text] [Related]
13. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
[TBL] [Abstract][Full Text] [Related]
14. Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer.
Wallis CJD; Satkunasivam R; Herschorn S; Law C; Seth A; Kodama RT; Kulkarni GS; Nam RK
Urol Oncol; 2018 May; 36(5):241.e1-241.e6. PubMed ID: 29503141
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
17. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer.
Agarwal M; Canan T; Glover G; Thareja N; Akhondi A; Rosenberg J
Curr Oncol Rep; 2019 Aug; 21(10):91. PubMed ID: 31446509
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]